BioNTech

Oncology

ASCO 2025 interview with Annemarie Hanekamp

BioNTech’s ASCO 2025 oncology advances: New data on bispecif...

At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.

News

BioNTech flips its cancer bispecific to BMS for a big profit

Bristol Myers Squibb is spending big to avoid being left behind in the race to develop a much-touted class of bispecific antibodies for cancer.

News

FDA tightens heart tox warnings on mRNA COVID vaccines

The FDA has instructed Pfizer and Moderna to add stronger warnings to the labels of their COVID-19 vaccines about the risk of cardiotoxicity.

News

UK trumpets £1bn investment plan from BioNTech

BioNTech has said it will commit up to £1bn in investment in the UK over the next decade, in what has been described as a "template" for the sector.

Sales & Marketing

Veeva Summit - Chris Moore, president of Veeva Europe

A next-generation mindset: Veeva Commercial Summit 2024

Imagine a time when all your teams collaborate seamlessly. That’s what this year’s Veeva Commercial Summit posited as it commenced.

News

BioNTech buys Biotheus and its Keytruda rival for $950m

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.

BioNTech’s ASCO 2025 oncology advances: New data on bispecif...

BioNTech flips its cancer bispecific to BMS for a big profit

FDA tightens heart tox warnings on mRNA COVID vaccines

UK trumpets £1bn investment plan from BioNTech

A next-generation mindset: Veeva Commercial Summit 2024

BioNTech buys Biotheus and its Keytruda rival for $950m

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

BioNTech

Editor's Picks